The Efficacy of L-cysteine in Prevention of Headache Attacks in Migraine Patients

• Status: Completed
• Trial end date: 2020-09-07
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to validate the novel hypothesis that daily use of L-cysteine (Acetium® capsules) is an effective means to decrease the frequency of (or completely abort) the headache attacks in migraine patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Biohit Oyj
• Collaborator: The Finnish Funding Agency for Technology and Innovation (TEKES)

Criteria

Inclusion Criteria:

• 18-65 years male/female

• subjects should report migraine attacks with the frequency of 2-8 times per month, and with less than 15 migraine days (NMD) per month. To be calculated as a separate attack, there should be at least 48h of freedom from headache between the two attacks of migraine.

• migraine with or without aura has been present for at least 1 year prior to entering into the study

• subjects to be enrolled should report the onset of their migraine before 50 years of age

Exclusion Criteria:

• patients who meet the International Classification of Headache Disorders II criteria for medication overuse

• patients who have taken anti-psychotics or anti-depressant medications during the previous 3 months

• patients who abuse alcohol or other drugs

• patients resistant to all acute migraine drugs optimally prescribed

• potentially fertile and sexually active women who do not practise contraception

• other acute or chronic pain disorders

• severe psychiatric disease

• infection

• malignancy

• short life expectancy

• cardiovascular disease

• cerebrovascular disease

• uncontrolled hypertension

• degenerative central nervous system diseases

• pregnant and lactating women

• regular users of Acetium capsules for other indications

• persons suffering from renal dysfunction or cystinuria